The PDE4 inhibitor roflumilast reduced bleomycin-induced pulmonary fibrotic and vascular remodeling in mice in vivo Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008
VIP prevents and reverses monocrotaline-induced PAH: Further protection by combination with bosentan Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010
Effects of chronic nitric oxide inhibition on eosinophil recruitment and extracellular matrix remodelling in chronic pulmonary inflammation Source: Eur Respir J 2007; 30: Suppl. 51, 735s Year: 2007
Effects of corticosteroid or montelukast associated to iNOS inhibitior on inflammation and remodelling of distal lung in animals with chronic inflammation Source: Annual Congress 2011 - Translational models of disease Year: 2011
Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003
Sildenafil enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002
iNOS-derived nitric oxide contributes to lung remodelling in an elastase-induced emphysema model Source: Annual Congress 2010 - Proteases and the matrix Year: 2010
Effects of corticosteroid or montelukast associated to iNOS inhibition on inflammation and remodelling of distal lung in animals with chronic inflammation Source: Annual Congress 2010 - Models of airways disease Year: 2010
Inducible nitric oxide synthase inhibition modulates lung tissue extracellular matrix remodelling induced by chronic allergic inflammation Source: Annual Congress 2007 - New treatments for asthma and COPD - experimental evidence Year: 2007
Comparative effects of inhaled nitric oxide and aerosolized iloprost during vasoreactivity testing in chronic pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005
The vasodilator response to inhaled nitric oxide (iNO) predicts the short term evolution with oral vasodilators in pulmonary arterial hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001
Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001
Roflumilast, a PDE4 inhibitor, improves lung function in patients with COPD treated with tiotropium Source: Annual Congress 2009 - Treatment of COPD Year: 2009
Interaction between nitric oxide, dexamethasone and montelukast controlling airway chronic inflammatory cell recruitment in guinea pigs Source: Eur Respir J 2004; 24: Suppl. 48, 350s Year: 2004
Simvastatin and sildenafil combine to attenuate pulmonary hypertension Source: Eur Respir J 2009; 34: 948-957 Year: 2009
Oral administration of a new prostacyclin agonist with thromboxane synthase inhibitory activity improves bleomycin-induced lung fibrosis Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010
Inhibition by roflumilast vs cilomilast of pulmonary leukocyte accumulation and TNFα release in a rat model of LPS-induced pulmonary neutrophilia Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003
Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004
A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010
Oral N-acetylcysteine attenuates the rat pulmonary inflammatory response to antigen Source: Eur Respir J 2003; 21: 394-400 Year: 2003